Washington Biotechnology
  • In Vivo CRO Services
    • Autoimmune & Inflammatory Diseases
      • Multiple Sclerosis
      • Gout
      • Inflammatory Bowel Disease (IBD)
      • Dermatitis (Contact)
      • Lupus
      • Nephritis
      • Pancreatitis
      • Hepatitis
      • Psoriasis
      • Pulmonary Fibrosis
      • Diabetes
      • General Inflammation Assessment
      • Acute Choleostasis Model
    • Rheumatoid Arthritis
      • Collagen-Induced Arthritis Model
      • Adjuvant-Induced Arthritis Model
      • Carrageenan Air Pouch Model
      • Zymosan Air Pouch Model
      • Pristane-Induced Arthritis Model
      • Ovalbumin-Induced Arthritis Model
      • SCW PG-PS 10S Rat Model
      • Arthritis Combo Testing: Rodent/Rabbit
    • Cancer
      • WBI Cell Lines for Cancer Models
      • Xenograft, Orthotopic & Syngeneic Models
    • Bacterial Infection
      • MRSA Model
      • Listeria Model
    • Pain Studies
      • Formalin Test (Chemical Sensitivity)
    • Pharmacokinetics and Toxicity
      • Pharmacokinetics (PK)
      • Toxicity and MTD Studies
    • Support Services
      • In Vitro Compound Screening for Anti-inflammatory Activity
    • WBI Project Management
  • About Us
  • What's New
  • Contact Us
  • Sitemap
  • Careers
  • In Vivo CRO Services
    • Autoimmune & Inflammatory Diseases
    • Rheumatoid Arthritis
      • Collagen-Induced Arthritis Model
      • Adjuvant-Induced Arthritis Model
      • Carrageenan Air Pouch Model
      • Zymosan Air Pouch Model
      • Pristane-Induced Arthritis Model
      • Ovalbumin-Induced Arthritis Model
      • SCW PG-PS 10S Rat Model
      • Arthritis Combo Testing: Rodent/Rabbit
    • Cancer
    • Bacterial Infection
    • Pain Studies
    • Pharmacokinetics and Toxicity
    • Support Services
    • WBI Project Management
  • About Us
  • What's New
  • Contact Us
  • Sitemap
  • Careers

SCW PG-PS 10S Rat Model

 

PG-PS 10S (peptidoglycan-polysaccharide polymer) administration induces a biphasic inflammatory response in rats, which includes an acute and/or chronic inflammatory phase. As such it provides a valuable model for assessment of the efficacy of therapeutic and prophylactic compounds on the acute and chronic inflammatory responses, especially for arthritis studies. A test compound in this model may show efficacy in acute or chronic (or both) phases of the inflammatory response. The efficacy pattern revealed may be a useful guide to the mechanism of action for the therapy and hence to the drug development program.

PG-PS 10S is a glycoprotein polymer isolated and purified from the cell wall of Streptococcus pyogenes. Administration of PG-PS 10S in rat induces responses which are representative of naturally caused inflammatory disorders (chronic, erosive, remittent arthritis, granulomatous entercolitis (resembling Crohn’s disease), intestinal hemorrhage, carditis and vasculitis). It is used most frequently in the rat intra-articular injection model for arthritis.

In our PG-PS 10S Rat Model an initial acute inflammatory response is seen within 3-6 days post-injection followed by a decline. A chronic response follows with a peak in measurements at approximately 12-16 days post-PG-PS 10S. The inflammatory response is quantitated by measurement of animal ankle widths by digital caliper.

The PG-PS 10 S Rat Model allows evaluation of compound efficacy for acute and/ or chronic inflammatory phases:

  • An initial acute inflammatory response is seen within 3-6 days post-injection followed by a decline.
  • A chronic response follows with a peak in measurements at approximately 12-16 days post-PG-PS 10S                                             

In this model an initial acute inflammatory response is seen within 3-6 days post-injection followed by a decline. A chronic response follows with a peak in measurements at approximately 12-16 days post-PG-PS 10S. The inflammatory response is quantitated by measurement of animal ankle widths by digital caliper.

A typical inflammatory response graph is shown below with the anti-inflammatory dexamethasone serving as a positive therapeutic control.

 

PG-PS 10S Rat Model

Allows evaluation of compound efficacy for acute or chronic (or both) inflammatory phases

  • An initial acute inflammatory response is seen within 3-6 days post-injection followed by a decline.
  • A chronic response follows with a peak in measurements at approximately 12-16 days post-PG-PS 10S.
Species Rat
Groups 6-10
Study Duration 22 days
Readouts animal ankle widths

 

 

Contact Us
Request a Quote
What's New?
Read Our Newsletter

© Washington Biotechnology Inc., 2014. All Rights Reserved.
Built by Biz-Zone